Company Overview and News
YUM! Brands (YUM) fits the millennial portfolio. The company claims two top 100 spots in the 'millennials favorite brands' list. Management is shareholder friendly and has a clear goal of increasing the ownership of existing shareholders by buyback programs. YUM! Brands' management shot the arrow exactly in the bull's eye with its partnership with Grubhub (GRUB). I prefer YUM! Brands over YUM China (YUMC) because it offers more diversity while still getting a license fee from its former Chinese subsidiary.
YUM GRUB MCD
Starbucks (NASDAQ:SBUX) is facing numerous issues it needs to address to prevent further loses in its stock price. Company shares are down over 10% for the year, and Howard Schultz has recently announced his departure as chairman. Schultz's news comes at a precarious time for Starbucks, as the company struggles with sluggish sales and a range-bound stock price. Given these developments, media outlets, including Barron's, have speculated activist interest in the company.
DNKN SBUX MCD CMG
Here's one from the Wonders Never Cease Dept.: When I say the Dividend Growth 50 has been "kindered," this time, it's actually a good thing!
GIS CAT XOM KMI.WS WMT COP NEE.PRI NEE.PRJ TGT V KMI.PRA KMI JNJ NEE.PRC AAPL NEE.PRQ NEE.PRR SBUX KMR CVB KMRFZ MCD NEE
Domino's Pizza, Inc. (DPZ - Free Report) , which is scheduled to report second-quarter 2018 earnings on Jul 19, will be under investors’ purview. Investors will not just look at the company’s top- and bottom-line performances but closely observe its comparable sales (comps) performance as well.
POOL GTT WING CAKE MCD
Today is National French Fry Day 2018 and McDonald’s (NYSE:MCD) has a special deal for customers.
Shares of Starbucks (SBUX - Free Report) popped again Friday as part of a nearly week-long climb. Despite this recent surge, SBUX stock is still down big over the last year. So what has investors excited about the coffee giant again, and is now the time to buy Starbucks on the dip?
In business and in life, you are allowed leeway for certain mistakes. But some unforced errors are not only inexcusable, they are intractably damaging, perhaps crippling. Papa John’s (NASDAQ:PZZA) founder John Schnatter found this out the hard way. Inexplicably, Schnatter used the N-word during a May conference call. His subsequent admission and apology cratered PZZA stock.
YUM MCD PZZA
Darden Restaurants, Inc.’s (DRI - Free Report) effective sales-boosting initiatives and synergies from Cheddar’s acquisition put the company on growth trajectory. However, high costs related to restaurant operations and stiff competition remain major concerns.
YUM DRI MCD
41 of 53 S&P 500 Dividend Aristocrats stocks were deemed "safer" for dividends because they showed positive one-year returns and free cash flow yields greater than their dividend yields 7/9/18.
GD KMB SWK PEP JNJ CINF CVX ITW DOV ABBV ABBV LEG MCD
There a few stocks I’ve consistently been bullish on for the past few years. And then there are also a few stocks which I’ve been consistently bearish on for a few years. Starbucks (NASDAQ:SBUX) stock falls in the latter category. I always looked at Starbucks stock as a case of a slowing growth story converging on a premium valuation.
I was a skeptic toward McDonald’s (NYSE:MCD) for some time. MCD stock took off in late 2015, not long after CEO Steve Easterbrook took over. MCD bulls pointed to strong same-restaurant sales numbers. But I argued through 2016 that the seeming improvement under Easterbrook was coming from easy year-prior comparisons, not necessarily a massive improvement in the business.
LW YUM KO MCD DPZ
23 of 30 Dow Industrial Index stocks were tagged as "safer" for dividends because they showed positive 1-year returns and free cash flow yields greater than their dividend yields as of 7/5/18.
MTSI PG TRV CAT WBA UTX DWDP VZA JNJ CVX CSCO VZ BA INTC PFE MCD MMM
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to MCD / McDonald's Corp. on message board site Silicon Investor.
as of ET